Jan 2018 Two steps forward, one step back: an opinionated take on NEJM highlights for January 2018 By Marc Herant NEJM Playing chess against cancer Tumors are not intelligent, but, because … Read more
Apr 2017 A population health approach to value-based drug pricing By Marc Herant Biopharma , Payers Working Paper Summary Drug companies are naturally incentivized… Read more
Jun 2014 Can drug companies make drugs, AND money? By Nikhil Bhojwani Biopharma , Payers In this morning’s New York Times (June 3,2014), Andrew Ross Sorkin ask… Read more
Aug 2011 ESRX-MHS Part 2: mail facility speculations (…or: Indulging my Inner SWAGer) By Tory Wolff Payers Summary ESRX was running at close to maximum capacity at its mail fa… Read more
Jul 2011 ESRX-MHS Part 1: Last stand of the PBM pure play: observations on the Medco-Express combination By Tory Wolff Payers UNH’s decision to take the commercial PBM business in-house did not fo… Read more
